Cocaine and methamphetamine both increase dopamine by blocking the dopamine transporter (DAT), but via different mechanisms: cocaine is a competitive antagonist, while methamphetamine also releases dopamine by reversing DAT via amphetamine-type release. Both produce brief intense euphoria through accumbens dopamine surge followed by rapid offset, creating powerful negative reinforcement driving compulsive use. Chronic use produces hypofunctional dopamine systems (reduced D2 receptor availability), anhedonia, and cognitive impairment.
Use microdialysis or fast-scan cyclic voltammetry to measure real-time dopamine changes during cocaine vs methamphetamine administration. Compare dopamine transporter availability in addicted vs control subjects using PET imaging.
Both cocaine and methamphetamine increase dopamine, but via distinct mechanisms—cocaine blocks uptake while methamphetamine actively reverses it, explaining different addiction trajectories and neurotoxicity.
From your study of monoamine synthesis and catabolism, you know that after dopamine is released into the synapse, the dopamine transporter (DAT) acts like a vacuum — it pumps dopamine back into the presynaptic neuron for repackaging or degradation. This reuptake is the primary off-switch for dopaminergic signaling. Both cocaine and methamphetamine disable that off-switch, but they do it in fundamentally different ways, with important consequences for their neurotoxicity and addiction potential.
Cocaine is a competitive reuptake inhibitor — it binds directly to the DAT and physically blocks the transporter's binding pocket. Dopamine already in the synapse cannot be cleared, so it accumulates and keeps stimulating postsynaptic receptors. Crucially, cocaine does not itself trigger release; it only prevents clearance. The effect is rapid and short-lived, because cocaine is quickly metabolized (plasma half-life of about 60 minutes). This creates a steep spike-and-crash dopamine profile, and the intense craving following offset drives repeated dosing. Cocaine also blocks norepinephrine and serotonin transporters, contributing to cardiovascular effects and mood disruption.
Methamphetamine works via a more aggressive mechanism. As an amphetamine-type compound, it enters the presynaptic terminal (partly through DAT itself) and causes reverse transport — it literally forces DAT to run backwards, flooding the synapse with dopamine from the cytoplasm regardless of vesicular release. This bypasses the normal action potential requirement for release. The result is a much larger and more prolonged dopamine surge. Methamphetamine is also lipid-soluble enough to cross into mitochondria and inhibit oxidative phosphorylation, generating reactive oxygen species. This oxidative stress, combined with the massive dopamine flood, causes direct damage to dopaminergic terminals — especially in the striatum and prefrontal cortex — explaining methamphetamine's greater long-term neurotoxicity compared to cocaine.
From your knowledge of D1 and D2 receptor subtypes and their downstream G-protein signaling, the consequences of chronic overstimulation become predictable. Postsynaptic neurons exposed to persistently elevated dopamine downregulate receptor density, particularly D2 receptors in the nucleus accumbens. PET imaging studies confirm dramatically reduced D2 availability in people with stimulant use disorder, even after months of abstinence. This hypodopaminergic state produces anhedonia — the inability to experience normal pleasure — because the reward system's gain has been chronically turned down to compensate for artificial overstimulation. The user now needs the drug to feel normal, not just to feel good. The transition from wanting the drug for pleasure to needing it to avoid the misery of its absence is the shift from positive to negative reinforcement that defines compulsive use.
No topics depend on this one yet.